secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0001437749-22-028072
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex licenses Univ. of Pittsburgh gene therapy for diabetes; milestones up to $4M
--------------------------------------------------------------------------------

- Worldwide exclusive license for gene therapy modulating autoimmunity to treat diabetes.
- Genprex pays initial license fee, single-digit running royalties, and low double-digit sublicense income share.
- Milestone payments aggregate up to ~$4M; annual minimum royalties after first commercial sale.
- Licensee must meet development milestones and use diligent efforts to commercialize.
- Agreement term runs 20 years after first commercial sale or expiration of last patent claim.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774922028072/0001437749-22-028072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774922028072/gnpx20221024_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-028072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer